## Key Lab of Health Technology Assessment, National Health Commission (Fudan University)

WHO Collaborating Centre for Health Technology Assessment and Management

# CHIA

# **NEWSLETTER**

July 2022 / Issue 2



### **HIGHLIGHTS**

- HTAi 2022 Annual Meeting was held on June 25- 29, 2022 in Utrecht, Netherlands and virtually.
- KLHTA/WHOCC faculty and students presented research findings of health technology assessment (HTA) and health systems research at HTAi 2022 Annual Meeting on virtual platform.
- Highlights of HTAi 2022 Annual Meeting are presented in this issue of newsletter.

# KLHTA/WHOCC Faculty and Students Participated in HTAi 2022 Annual Meeting

The Health Technology Assessment international (HTAi) 2022 Annual Meeting was held in Utrecht and virtually June 25-29, 2022. With the theme of "Lifecycle Approach: Coming Together to Make it Happen", the conference organized three plenary sessions titled "Adopting a Lifecycle Approach in HTA: Consequences for Priority Setting and International Collaboration", "Public Confidence in Healthcare Decision-Making" and "Running Around in Circles; Time for Real Collaboration between Regulators, HTA Bodies and Clinicians", respectively.

The conference also provided a range of workshops, panels, oral presentations and posters, which gathered international attendees to share the latest research progress, advancing discussions in policy and methods and building global networks deeply and extensively.

Professor Yingyao Chen and graduate students attended this conference virtually. The Key Lab faculty and students successfully organized and participated in one panel session titled "Working Together in Health Technology Assessment on Oncology Immunotherapy Lifecycle: Opportunities and Challenges in East Asia".



KLHTA/WHOCC NEWSLETTER 2022 / ISSUE 2

At the panel session, four panelists made in-person or virtual presentation on immunotherapeutic drugs approval and corresponding reimbursement policies in China, Japan, and South Korea. Professor Yingyao Chen shared the current policies of HTA for oncology immunotherapy lifecycle in China, and analyzed the opportunities and potential challenges. Professor Jeonghoon Ahn and Dr. Ruoyan Gai concentrated the health technology assessment conduction for immuno-oncology drugs in Korea and Japan respectively. Professor Lizheng Shi summarized the opportunities and challenges to enhance regional collaboration in HTA. And a heated discussion was occurred between presenters and audiences after presentations.

The Key Lab graduate students also presented 1 oral presentation and 5 poster presentations, covering topics of the reporting quality of pharmacoeconomic evaluations, health-related quality of life, treatment and effects assessment, etc. Although the Key Lab faculty and students attended the conference via a virtual platform, they showed the future directions of health technology assessment through oral and poster presentations to scholars and professionals around the globe and received wide praise.



KLHTA/WHOCC NEWSLETTER 2022 / ISSUE 2



Faculty and students from the Key Lab were able to gain insight into the most advanced health technology assessment research, engage in extensive communication with leading academics from around the world, showcase the most recent findings from the Key Lab's researches, and broaden their network of international collaborators by attending this conference. The faculty and students of the Key Lab have improved the global influence of the Key Lab, Fudan University and China's Health Technology Assessment, and have set the stage for future advancements in the quality of research conducted at the lab and in its ability to translate findings into practice.

### Titles of the Key Lab's Presentations at the Conference:

### Panel:

Working Together in Health Technology Assessment on Oncology Immunotherapy Lifecycle: Opportunities and Challenges in East Asia

### **Oral Presentations:**

Assessing the Quality of Pharmacoeconomic Evaluations about Type 2 Diabetes Mellitus Drugs in National Reimbursement Drug List (Shiyi Bao; sybao2o@fudan.edu.cn)

### **Poster Presentations:**

Health-Related Quality of Life and Utility Scores of Lung Cancer Patients Treated with Traditional Chinese Medicine in China (Liu Liu; liuliu20@fudan.edu.cn)

Quality of Economic Evaluation of Coronary Stents Based on CHEERS: A Scoping Review (Yanfeng Ren; renyf2o@fudan.edu.cn)

Quality Assessment of Health Economic Evaluation on Screening Programs from China (Yu Xia; xiay20@fudan.edu.cn)

A systematic review of reporting quality of economic evaluations in TCM in NRDL of China based on CHEERS (JuntaoYan; jtyan2o@fudan.edu.cn)

A Literature Review of Treatment Schemes and Effects of Beta-thalassemia in China (Jiaqi Yuan; jqyuan21@m.fudan.edu.cn)

# Lifecycle Approach: Coming Together to Make it Happen Highlights of the HTAi Annual Meeting (HTAi 2022)

During June 25-29, 2022, the 2022 HTAi Annual Meeting with the theme of "Lifecycle Approach: Coming Together to Make it Happen" took place in Utrecht, Netherlands. Key Lab faculty and students participated in the conference virtually. Here we summarize some of the highlights based on three plenary sessions of the conference- "Adopting a Lifecycle Approach in HTA: Consequences for Priority Setting and International Collaboration", "Public Confidence in Healthcare Decision-Making" and "Running Around in Circles; Time for Real Collaboration between Regulators, HTA Bodies and Clinicians".

# Highlight 1: Adopting a Lifecycle Approach in HTA: Consequences for Priority Setting and International Collaboration

The first plenary session titled "Adopting a Lifecycle Approach in HTA: Consequences for Priority Setting and International Collaboration" directly showed attendees the importance of a life-cycle strategy in HTA practice and the potential challenges today.

It is highly likely that the adoption of a life-cycle strategy in HTA will have far-reaching consequences for the practice of HTA. In addition to a great number of other things, it will heighten the need of setting priorities and collaborating internationally. The implications of implementing a life-cycle approach were discussed from a variety of dimensions, including: where we are now, how we are going to make the transition, and what are the potential risks and rewards that are associated with this approach during this plenary.

### Highlight 2: Public Confidence in Healthcare Decision-Making

The COVID19 pandemic has sparked a debate about the legitimacy of healthcare decision-making unlike any other time in recent history. It has brought to light considerable disparities in public worldviews, such as people that are suspicious of science and distrust governments as well as health care systems. In this environment, the Health Technology Assessment (HTA) relies on the faith of the public for both its funding and the implementation of its recommendations or advice. This plenary focused the nature of public confidence and the ways in which it may affect how we rethink the function of HTA in the lifespan and the societies in which we live. It elicited different stakeholders' experiences of integrating perspectives in HTA and challenged the community to take a critical view of HTA's contribution to public confidence in health and science.

# Highlight 3: Running Around in Circles; Time for Real Collaboration between Regulators, HTA Bodies and Clinicians

During the course of a health technology's lifecycle, regulators, HTA bodies, and clinicians may offer recommendations regarding the (cost-)effectiveness of various health technologies. Their suggestions could not always coincide, which could result in difficulties in gaining access to these technologies, delays,

KLHTA/WHOCC NEWSLETTER 2022 / ISSUE 2

and a lack of clarity for both patients and medical personnel. Throughout the lifecycle of a health technology, a variety of evidence, such as randomized controlled trials (RCTs) or data from clinical practice, may be available to support recommendations; however, these types of evidence may be perceived differently.

(Edited by Yu Xia, resource from https://www.htai2o22.org/)

### **International Conference Information**

HTAi 2023 Annual Meeting will be held in Adelaide, Australia during June 24<sup>th</sup> and June 28<sup>th</sup> with the theme of "The Road to Policy and Clinical Integration". For abstract submission and registration details, please visit: <a href="https://www.htai2023.org">https://www.htai2023.org</a>

The 15<sup>th</sup> China Health Technology Assessment Forum will be held in Shanghai, China, during November 2022, the theme of this forum is "Innovative methods and decision-making practices". Policymakers, researchers, and others are cordially invited to register for the conference. For more details, please visit: http://chinamed-ce.com/hta2021/index.asp





Key Lab of Health Technology Assessment, National Health Commission (Fudan University) / WHO Collaborating Centre for Health Technology Assessment and Management

July 2022 / Issue 2 Editor: Yu Xia P.O.Box 197, No 138, Yi Xue Yuan Road, Shanghai, 200032

Tel: 86-21-33565190

Email: cwchen@shmu.edu.cn
Website: https://chta.fudan.edu.cn/